{"title":"Faecal microbial transplant","authors":"Isreal Ayobami Onifade , Oluwatomiwa Jubilee Sunbare-Funto , Chinedu Endurance Mbah , Oluwatosin Akinola Ajibade , Olubukola Monisola Oyawoye , Abdullahi Tunde Aborode , Seto Charles Ogunleye , Abdullahi Jamiu , Basit Bolarinwa , Mosope F. Abanikannda , Zainab Tiamiyu , Abidemi Ruth Idowu , Oluwatobiloba Ige , Opara Julia Kelechi , Jeremiah I. Abok , Eniola A. Lawal , Ibude Jane Aruorivwooghene , Adekunle Fatai Adeoye , Olowo Roqeebah , Emmanuel Akinloye Ojewole , Ridwan Olamilekan Adesola","doi":"10.1016/j.abst.2024.02.001","DOIUrl":null,"url":null,"abstract":"<div><p>Faecal Microbial Transplantation (FMT), have been shown to be successfully managed along with a variety of gastrointestinal disorders, including <em>Clostridioides difficile</em> infection (CDI), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). FMT is a medical procedure that involves a donor transferring healthy gut bacteria to the recipient. The effectiveness of FMT is thought to be due to the ability of the healthy gut to restore balance to the recipient's microbiome, which is the community of microorganisms that inhabit the gastrointestinal tract. One of the key advantages of FMT is that it is a relatively simple and low-cost treatment option, compared to other therapies that may be more invasive or require long-term medication use. However, FMT is not without its limitations, including the potential for the transfer of infectious agents from the donor to the recipient and the potential for negative side effects in some patients. In this research, we discuss the current state of the evidence on FMT, including its potential benefits and risks, as well as future directions for research in this area.</p></div>","PeriodicalId":72080,"journal":{"name":"Advances in biomarker sciences and technology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2543106424000036/pdfft?md5=2c2f7c6deba6132e414ddec7623c4461&pid=1-s2.0-S2543106424000036-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in biomarker sciences and technology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2543106424000036","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Faecal Microbial Transplantation (FMT), have been shown to be successfully managed along with a variety of gastrointestinal disorders, including Clostridioides difficile infection (CDI), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). FMT is a medical procedure that involves a donor transferring healthy gut bacteria to the recipient. The effectiveness of FMT is thought to be due to the ability of the healthy gut to restore balance to the recipient's microbiome, which is the community of microorganisms that inhabit the gastrointestinal tract. One of the key advantages of FMT is that it is a relatively simple and low-cost treatment option, compared to other therapies that may be more invasive or require long-term medication use. However, FMT is not without its limitations, including the potential for the transfer of infectious agents from the donor to the recipient and the potential for negative side effects in some patients. In this research, we discuss the current state of the evidence on FMT, including its potential benefits and risks, as well as future directions for research in this area.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
